GonaCon,™ a versatile GnRH contraceptive for a large variety of pest animal problems by Miller, Lowell A. et al.
UC Agriculture & Natural Resources
Proceedings of the Vertebrate Pest Conference
Title
GonaCon,™ a versatile GnRH contraceptive for a large variety of pest animal 
problems
Permalink
https://escholarship.org/uc/item/4x75n4pq
Journal
Proceedings of the Vertebrate Pest Conference, 21(21)
ISSN
0507-6773
Authors
Miller, Lowell A.
Rhyan, Jack
Killian, Gary
Publication Date
2004
eScholarship.org Powered by the California Digital Library
University of California
GonaCon"', a Versatile GnRH Contraceptive for a Large Variety of Pest 
Animal Problems 
Lowell A. Miller 
USDA APIDS Wildlife Services, National Wildlife Research Center, Fort Collins, Colorado 
Jack Rhyan 
USDAAPIDS Veterinmy Services, National WildlifeReseareh Center, Fort Collins, Colorado 
Gary Killian 
Almquist Researeh Center, Peon State University, University Park, Pennsylvania 
ABsTRAcr: As part of the program to develop contraceptive tools to control populations of over-abundant wildlife species, the 
NWRC has developed a single-injection gonadotropin-releasing hormone (GnRH) immunocontraceptive vaccine, GonaCon "'. 
GonaCon"' has been tested and shown to provide contraceptive effects lasting 1-3 years in many pest species including white-tailed 
deer, domestic and feral pigs, bison, wild horses, cats, dogs, and California ground squirrels. GonaCon"' contains a GnRH peptide 
conjugated to keyhole limpet hemocyanin combined with AdjuVac"', an adjuvant also developed at the USDA National Wildlife 
Resemch Center. Immunization against GnRH prevents the cin:ulating GnRH from stimulating the release of pituitary luteinizing 
honnonc and folliclo-stimulating hormone. This process of immuno-neut:rali7.ation of GnRH effects a temporary non-surgical 
castration in both males and females. Contraceptive and behavioral effects of GonaCon""' are discussed for a variety of species. 
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INTRODUCTION 
A growing interest in nonlethal methods for 
population control of nuisance or damaging species of 
wildlife has fostered researeh in reducing fertility of these 
pest wildlife species. The most commonly used means of 
inducing infertility is by immunocontraception, in which 
the animal is immunized against a protein or hormone 
needed for reproduction. Wildlife personnel have looked 
at the values and shortcomings of immunocontraception 
for several years and all have concluded that further 
research is wmanted (Miller and Fagerstone 2000, 
Fagerstone et al. 2002). 
Traditional immunocontraceptive researeh in 
mammals has concentrated on the use of a vaccine made 
from zona pellucida extracted from the ovaries of pigs 
(Sus scrofa) and therefore called porcine zona pellucida 
(PZP) (Miller et al. 1999). Animals immunocontracepted 
with PZP continue to cycle and are bred, but they do not 
become pregnant due to the PZP antibody coating the 
egg. In animals such as white-tailed deer ( Odocoileus 
virginianus) that continue to cycle throughout the 
breeding season, the PZP contraceptive technique may 
introduce physiological stress due to an extended 
breeding season (Killian and Miller 2000, Miller and 
Killian 2000). This prolonged estrous cycling results in 
increased activity during early winter, at a time when 
conservation of calories is important. Increased activity 
may also contnlnrte to increased collisions with 
automobiles in highly populated areas. Because of 
concerns over prolonged estrous cycling,, NWR.C 
developed a second contraceptive (GnRH vaccine) that 
contracepts by reducing reproductive behavior. · 
Proc.21•vertebr. PestConf.(R M. Timm andW. P. Gonm.el,Eds.) 
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DEVELOPMENT OF THE GnRHVACCINE 
GnRH (gonadotropin-releasing hormone) is a small 
peptide hormone sometimes called the "master hormone" 
because it is responsible for controlling the reproductive 
processes in both males and females. The GnRH peptide 
is identical in all mammals and is not immunogenic both 
because of its small size and because it is considered 
"self' to the immune system. However, GnRH can be 
made immunogenic by coupling it to a carrier such as 
keyhole limpet hemocyanin (KLH). The coupled GnRH 
peptide is called a GnRH conjugate, which then is 
combined with an adjuvant to create a vaccine. 
GnRH contraceptive vaccines have been evaluated as 
immunocastration agents in pets, (cats, Felis sylvestris 
catus; and dogs, Canis familiaris), cattle (Bos taurus), 
sheep (Ovis aries), swine, and deer (Odocoileus spp.) 
(Adams and Adams 1992, Ladd et al. 1994, Meloen et al. 
1994, Oonk et al. 1998, and Schanbacher 1982). All of 
these GnRH studies have used 2 or more injections, and 
the duration of the immune responses in many studies has 
been 6 months or less, which is not practical for wildlife 
applications. 
The first application of the NWR.C GnRH vaccine 
was a GnRH/keyhole limpet hemocyanin (KLH)/ 
Freund's combination, which was tested in the Noiway 
rat (Rattus norvegicus). In this study, which used a prime 
and a boost vaccination (Miller et al. 1997), both male 
and female rats remained infertile for up to 1 year. The 2-
injection GnRH vaccine was then tested in white-tailed 
deer. Details of this study were reported in Miller et al. 
(2000). A commercial vaccine (Improvac) that required 2 
injections was available for a short time in Australia, 
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but it was recently taken off the market (Dunshea et al. 
2001). 
Because GnRH does not stimulate an immune 
response by itself, the success of the vaccine depends on 
the design of the conjugation. &ch of the previous 
authors mentioned above have their own GnRH 
conjugation design. Ferro et al. (2002a, 2002b) have 
studied several different designs of GnRH conjugation; 
however, they still required multiple injections. 
The design of a single-injection vaccine that will 
provide multi-year contraceptive effect requires 1) 
optimizing the vaccine structural design, 2) optimizing 
the dose for each target species, 3) adding the best 
adjuvant possible, and 4) designing a delivery system that 
will protect the injected antigen from rapid destruction by 
the immune system. The multi-injection vaccine is more 
forgiving in relation to dose and the optimum vaccine 
design. Details of the current GnRH vaccine developed 
by NWRC are presented in a previous article (Miller et al. 
2003). However, some general design concepts to 
improve the vaccine effectiveness are presented here. 
ADJUV ANT DESIGN (AdjuVacj 
An important part of any vaccine is the adjuvant (a 
non-specific immune stimulant). The most popular, and 
most controversial, adjuvant is Freund's Adjuvant, which 
has been widely used since 1945. This adjuvant has 
remained popular to immunologists over time because it 
is so effective with all types of antigens. It is now known 
that the addition of Mycobacterium in Freund's complete 
adjuvant (FCA) provides a vital "danger signal" to the 
immune system that is the key to Freund's success. 
Although many other adjuvants have been developed, 
none have matched the effectiveness of FCA However, 
because of the negative attitude of many animal care and 
use committees as well as Food and Drug Administration 
(FDA) concerns on the use of Freund's in any approved 
product, NWRC began testing a modified USDA-
approved Johne's vaccine, Mycopar ... , as a replacement 
for Freund's adjuvant Mycopar is approved for use in 
food animals and is therefore not a concern for use in 
deer, which may be eaten by hunters. 
The new adjuvant, which we have named AdjuVac ... , 
contains a small quantity of M. avium, a common bacteria 
found in many wildlife and domestic animaJs, which 
provides a similar "danger signal" to the immune system 
found in Freund's adjuvant. NWRC is currently testing 
AdjuVac,.. in many different wildlife species and it 
appears to be an effective replacement for Freund's as an 
adjuvant for immunocontraception. 
SINGLE-INJECTION GonaConno MIMICS 
BACTERIA 
Many pathogens, including viruses and bacteria, 
exluoit a rigid, highly organized, highly repetitive pattern 
of protein epitopes. This repetitive epitope pattern 
provides a cross-linking activation of B cell receptors, 
resulting in an extremely strong, long-lasting immune 
response (Bachmann et al. 1993). This mimic of the 
repetitive nature of pathogen epitopes is an important part 
of the Klll-GnRH conjugate design. Banatvala et al. 
(2001) state that the antigen dose and structure and 
repetitive eptitope pattern influence the strength of the 
primary response. He stresses that the greater the primary 
response, the longer lasting the immune memory. 
Bachmann et al. (1993) have shown that in obtaining a 
high B cell responsiveness to an individual epitope, the 
design of the immunogen is very important. They found 
that high epitope density in a highly organi7.ed repetitive 
fashion was important in B cell responsiveness. B cells 
were unresponsive to poorly-organi7.ed but repetitive 
epitopes. Repetitive epitopes of proper spacing are able 
to stimulate multiple surface receptors of similar spacing. 
Long-lasting immune response is thought to be due to a 
combination of persisting antigen, which is capable of B 
cell differentiation into plasma cells, and the persistence 
oflong-lasting plasma cells. 
The bacterial mimic Klll-OnRH conj~e design, 
combined with the new adjuvant (AdjuVacj, which 
contains small quantities of M avium, form the basis of 
the new multi-year single-injection GnRH vaccine 
GonaCon"'. 
EFFECT OF GonaCon""TREATMENT IN 
FEMALES 
Females are· treated with GnRH vaccine by 
intramuscular injection. Effectiveness of the vaccine is 
tested by measuring the anttDody levels to GnRH, and 
hormonal cyclic activity is measured by periodic 
sampling of serum concentrations of progesterone and 
estradiol. Effective contraception in fc.males reduces 
hormone levels to the point that females do not ovulate or 
come into estrus. In seasonal breeding animaJs such as 
the white-tailed deer, a non-cyclic state is normal 6 
months out of the year; GnRH-vaccinated females simply 
do not come into estrus in the full. Field ~ of the 
GnRH vaccine includes monitoring the breeding activity, 
followed by monitoring the reduction of offspring in the 
treated group as compared to the control group. 
GnRH vaccine has been tested in the female whi~ 
tailed deer for several years at both Pennsylvania State 
University and Seneca Army Depot. We have found that 
GnRH reduces breeding behavior and reduces fawning 
for up to 4 years (Miller and Killian 2000). 
EFFECTS OF GonaCon,.. TREATMENT IN MALES 
Males are treated with GnRH vaccine by intramuscu-
lar injection. Effectiveness of the vaccine is tested by 
measuring antibody levels to GnRH. Serum testosterone 
concentrations are also measured. Testicular size is 
measured, and sperm mobility and number are also 
measured. 
Effective contraception is the male is measured by the 
drop in testosterone levels, reduction in the size of the 
testicles, reduction in aggressive behavior, and the lack of 
interest in females that are in estrus. 
The GnRH has been injected in the male white-tailed 
deer at Pennsylvania State University and at Seneca 
Army Depot, where we found the annual growth of 
antlers in male deer is dependant on testosterone, with 
antler growth increasing with age and increased 
testosterone concentration. We have found large varia-
tion in the size of antlers in GnRH-treated male deer 
(Curtis et al. 2001). Depending on the timing of the 
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vaccination, the antlers could fall off early, stay in velvet, 
or have an abnormally small growth pattern. 
DURATION OF CONTRACEPTIVE EFFECT 
In animals treated with GnRH vaccine, anti-OnRH in 
the hypophyseal portal blood complexes to the newly 
released GnRH from the hypothalamus, preventing 
GnRH from binding to the follicle-stimulating hormone 
(FSH) and luteinizing honµone {Lll) receptors. GnRH is 
released from the hypothalamus in a pulse-related 
fashion; the frequency and high of the pulse is related to 
seasonal sexual activity or the phase of the estrus cycle. 
The concentration of newl~-released GnRH in the portal 
blood is picogram/ml (10- 2 grams/ml), and as it passes 
into the peripheral blood its concentration drops to 
femtogram/ml (lO·lS gram/ml). This concentration is too 
small to measure even by the most sensitive 
radioimmunoassay method. GnRH-antlbody complexes 
produced in the portal blood are destroyed by th~ immune 
system as they pass through the liver. Continued 
contraceptive effect is dependent on a continual source of 
available GnRH antibody. This small quantity of GnRH 
controls the concentration of the active reproductive 
hormones, progesterone and testosterone, which circulate 
at nanograms/ml .(10-9 grams/ml). It is this small quantity 
of a master hormone that makes it a good candidate for 
immunocontraception. 
In all the species tested, immunization with resulting 
antibody titer to GnRH leads to an inhibition of breeding 
behavior and contraception. Effective contraception 
continues as long as antibody titers remain sufficiently 
high. 
Effectiveness of the contraceptive response is dose 
related. Our research has determined that the effective 
dose can be divided into 3 general categories: small 
animal = 200 - 400 µg of conjugate, mid-sized animal = 
800 - 1,000 µg of conjugate, and large-sized animal = 
1,500 - 2,000 µg of conjugate. Intra-muscular injections 
appear to be the most effective route of delivery. All 
species show an apparent individual variation in immune 
response to the vaccine. In species where there was 
initially 100% contraception, there was always a variation 
between individuals in the length of the contraceptive 
response. 
EFFECTs OF GnRH ON MAMMALS 
GnRH Vaccine in California Ground Squirrels 
NWRC scientists in collaboration with staff from the 
Alameda County, California, Vector Control District 
tested the use of a single-injection GnRH in the California 
ground squirrel (Spermophilus beechey1). In the 2-year 
study, 229 male and female squirrels were trapped and 
injected with a single-injection GnRH preparation. 
Results suggest a significant reduction in lactation in 
females through the 2-year period, as well as a reduction 
in sexually-active males (Nash et al. 2004). 
I 
GnRH Vaccine in Feral Dogs and Cats 
GnRH vaccine has shown to be effective in reducing 
the testosterone, sperm count, and sperm motility in a 
small sample of test male dogs. The vaccine should be 
very effective in reducing reproductive activity in the 
female dog. The reproductive inhibition effect lasted 1 
year in the male dog with a single injection; however, the 
contraceptive effect should last longer in the female dog. 
NWRC has begun a collaborative study with GnRH in 
cats. The vaccine has reduced the testosterone and spenn 
counts in several male cats for up to 1 year with a single 
injection (Levy et al. 2004). Dr. Julie Levy from the 
University of Florida has received a Morris Foundation 
Grant for a collaboration with NWRC to study the 
reproductive effects of the GnRH in female cats. 
Comparing Contraceptives in Wild Horses 
In collaboration with Nevada State Veterinarian Dr. 
David Thain, researchers Dr. Jack Rhyan, Dr. Gary 
Killian, and Dr. Lowell Miller are comparing the effects 
of 3 contraceptive Techniques, SpayVac (a PZP formula-
tion), GonaCon .... , and insertion of an IUD, in state-owned 
wild horses in Nevada. The first year's data appear 
promising for all 3 techniques (Killian et al. 2004a). 
GnRH Vaccine Reduces Disease 
GnRH Vaccine in Feral Pigs 
Sexual transmission of pseudorabies in feral pigs has 
increased interest in the use of GnRH as a contraceptive, 
which reduces fertility by reducing breeding activity. The 
GnRH vaccine has been effective in reducing 
reproduction in domestic pigs (Miller and Killian 2004a). 
Feral swine are recognized as disease reservoirs for 
brucellosis and psuedorabies, among other diseases, and 
they increase the risk of disease spread to other wildlife, 
domestic livestock, and humans (Killian et al. 2004b). 
Although the porcine zona pellucida vaccine has been 
shown effective for contraception of several wildlife 
species (Fagerstone et al. 2002), its use in swine is 
problematic because the vaccine is prepared using 
porcine zona pellucida protein, which is a "self protein," 
making it less immunogenic in the pig. Also, as previ-
ously mentioned, immunocontraception with the PZP 
vaccine may cause treated females to continue to cycle, 
increasing the opportunity to spread pseudorabies. 
The GnRH vaccine may have an application in 
making male pigs more palatable by reducing boar taint. 
Dunshea et al. (2001) have shown that lmprovac (a 
commercial GnRH vaccine) reduced boar taint in adult 
male pigs. NWRC has unpublished studies that support 
these data both in domestic and feral pigs. 
GnRH Vaccine in Bison 
There are concerns over the spread of disease through 
calving, such as brucellosis in bison. Bovine brucellosis, 
a bacterial disease is transmitted between animals 
including cattle, bison (Bison bison), and elk ( Cervus 
spp.), primarily through contact with infected aborted 
fetuses, placentas, parturi~t fluids, or post-parturient 
uterine discharge. Following initial infection, a dam often 
experiences abortion. Subsequent pregnancies may result 
in abortion or the birth of weak or normal calves and may 
also result in shedding of the organism. Contraception 
may therefore reduce the spread of the disease. 
PZP is not an optimal contraceptive vaccine, because 
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prolonging the breeding season of bison in the Greater 
Yellowstone Area may be deleterious to winter survival 
of dominant bulls and vaccinated cows, due to increased 
activity in fall and early winter. Immunocontraccption 
using GnRH vaccine has been shown to reduce 
reproductive activity in the bison, and it is an alternative 
to PZP that would not extend the breeding season. 
Female bison in a 7.00 setting have been given two GnRH 
injections, which resulted in 100°/o reduction in calving 
for over 2 years. Penned female bison in Idaho, when 
given a single shot, have been contracepted for 1 year. 
Four out of S bison were in the third trimester of 
pregnancy at the time of GnRH vaccination and went on 
to deliver nonnal calves. The following year, none of the 
S bison calved (Miller et al. 2004). 
DISCUSSION 
lmmunocontraception through the use of GnRH 
vaccine has intrigued reproductive physiologists for 20 
years. The vaccine has been used to immunocastrate a 
variety of animals with mixed success. Because of the 
seasonal pulsating picogram quantity of GnRH, it 
becomes the most logical hormone to bioneutralize, and 
yet there is no GnRH vaccine on the market. Because 
GnRH must be linked to a large protein to make it 
immunogenic, the conjugate design has presented a 
limiting factor in developing a successful long-acting 
GnRH vaccine. The pi¢uct development program of 
NWRC has spent more than 10 years testing multiple 
vaccine designs in white-tailed deer. As a result of these 
studies, the current combination of the KLH-GnRH 
conjugate design, combined with a newly-devel<>ped 
adjuvant AdjuVac"", appears to provide an effective, 
long-lasting vaccine, which we have named GonaCon"'. 
GnRH vaccines have been criticized because of lack 
of species specificity. Because GnRH has a similar 
peptide sequence in all mammals, species specificity must 
come with the injection delivery method. The positive 
side of the lack of species specificity is that the same 
vaccine can be used for multiple species with slight 
variations in dosage. 
GnRH has also been criticized because it reduces the 
nonnal breeding behavior of the target animal. However, 
seasonal breeders exhibit breeding behavior for 6 months 
out of the year, so GnRH vaccine merely prolongs the 
lack of sexual interest throughout the year. At this point 
in time, there is no reproductive control method that does 
not in some way interfere with reproductive behavior. As 
GonaCon"' becomes available as a contraceptive vaccine, 
we should consider it a tool available for certain 
situations, while we continue to research new and 
improved control methods for future use. 
The GnRH vaccine GonaCon"' has been shown to be 
an effective s~e-injection immunocontraceptive 
vaccine. GonaCon is useful for many applications, one 
of which is reducing breeding behavior of a particular 
animal. Another application is to reduce aggression in 
males. For example, male deer in parks become quite 
used to people and can be fed in the non-breeding season; 
however during the breeding season, these male deer can 
become quite dangerous. A GnRH vaccination could 
reduce this aggressive behavior. The vaccine can be used 
as a single or multiple injections, and response is 
generally reversible in 1 to 4 ,:ears, depeoding on the dose 
given. The GnRH/AdjuVac vaccini, called GonaCon"', 
has an APHIS USDA patent-pending status. 
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